JP5004215B2 - 神経障害に伴う過活動膀胱の予防または治療用医薬組成物 - Google Patents
神経障害に伴う過活動膀胱の予防または治療用医薬組成物 Download PDFInfo
- Publication number
- JP5004215B2 JP5004215B2 JP2006510642A JP2006510642A JP5004215B2 JP 5004215 B2 JP5004215 B2 JP 5004215B2 JP 2006510642 A JP2006510642 A JP 2006510642A JP 2006510642 A JP2006510642 A JP 2006510642A JP 5004215 B2 JP5004215 B2 JP 5004215B2
- Authority
- JP
- Japan
- Prior art keywords
- neuropathy
- drugs
- overactive bladder
- pharmaceutical composition
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(Cc(cc1*)cc2c1N(*)CC2)NCCOc1ccccc1O* Chemical compound CC(Cc(cc1*)cc2c1N(*)CC2)NCCOc1ccccc1O* 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Description
(1)一般式
(2)有効成分が、(−)−1−(3−ヒドロキシプロピル)−5−((2R)−2−{[2−({2−[(2,2,2−トリフロロエチル)オキシ]フェニル}オキシ)エチル]アミノ}プロピル)−2,3−ジヒドロ−1H−インドール−7−カルボキサミドまたはその薬理学的に許容される塩である、前記(1)記載の医薬組成物;
(3)神経障害が、脳血管障害、パーキンソン病、脊髄障害、末梢神経障害または多発性硬化症である、前記(1)または(2)記載の医薬組成物;
(4)神経障害に伴う過活動膀胱に対して用いられる他の薬剤を1種以上組み合わせて使用される、前記(1)〜(3)のいずれかに記載の医薬組成物;
(5)神経障害に伴う過活動膀胱に対して用いられる他の薬剤が、抗コリン薬、抗不安薬、コリン作動薬、コリンエステラーゼ阻害薬、鎮痙薬、抗炎症薬、抗菌薬から選択される薬剤である、前記(4)記載の医薬組成物;等に関するものである。
エーテル麻酔下の雌ラットの脊髄をTh10部位で切断し、脊損手術を行った。脊損手術約1ヶ月後、ラットをペントバルビタールにて麻酔し、膀胱に生理食塩液を満たしたカテーテルを挿入し結紮し、頸背部より導出し栓をした。カテーテル挿入約7日後に、頸静脈にヘパリン加生理食塩液を満たしたカテーテルを挿入結紮し、頸背部より導出し栓をした。翌日に、覚醒無拘束のラットにてシストメトリーを行った。膀胱内には12 mL/hrの流速で生理食塩液を注入した。頸背部より導出された頸静脈カテーテルより薬物を投与した。その結果、雌ラット脊損モデルでは、蓄尿時に不随意収縮が認められた。化合物1の静脈内投与(0.1 mg/kg)は、同モデルの排尿間隔を約20%延長し(図1)、蓄尿時に生じた不随意収縮の発生頻度を約20%抑制した(図2)。
Claims (4)
- (−)−1−(3−ヒドロキシプロピル)−5−((2R)−2−{[2−({2−[(2,2,2−トリフロロエチル)オキシ]フェニル}オキシ)エチル]アミノ}プロピル)−2,3−ジヒドロ−1H−インドール−7−カルボキサミドまたはその薬理学的に許容される塩を有効成分として含有する、神経障害に伴う過活動膀胱の予防または治療用医薬組成物。
- 神経障害が、脳血管障害、パーキンソン病、脊髄障害、末梢神経障害または多発性硬化症である、請求項1記載の医薬組成物。
- 神経障害に伴う過活動膀胱に対して用いられる他の薬剤を1種以上組み合わせて使用される、請求項1または2記載の医薬組成物。
- 神経障害に伴う過活動膀胱に対して用いられる他の薬剤が、抗コリン薬、抗不安薬、コリン作動薬、コリンエステラーゼ阻害薬、鎮痙薬、抗炎症薬、抗菌薬から選択される薬剤である、請求項3記載の医薬組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006510642A JP5004215B2 (ja) | 2004-03-05 | 2005-02-23 | 神経障害に伴う過活動膀胱の予防または治療用医薬組成物 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004061476 | 2004-03-05 | ||
JP2004061476 | 2004-03-05 | ||
PCT/JP2005/002913 WO2005085195A1 (ja) | 2004-03-05 | 2005-02-23 | 神経障害に伴う過活動膀胱の予防または治療用医薬組成物 |
JP2006510642A JP5004215B2 (ja) | 2004-03-05 | 2005-02-23 | 神経障害に伴う過活動膀胱の予防または治療用医薬組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2005085195A1 JPWO2005085195A1 (ja) | 2007-12-13 |
JP5004215B2 true JP5004215B2 (ja) | 2012-08-22 |
Family
ID=34918068
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006510642A Expired - Fee Related JP5004215B2 (ja) | 2004-03-05 | 2005-02-23 | 神経障害に伴う過活動膀胱の予防または治療用医薬組成物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20070167511A1 (ja) |
EP (1) | EP1724257B1 (ja) |
JP (1) | JP5004215B2 (ja) |
KR (1) | KR20070003968A (ja) |
CN (1) | CN1930123B (ja) |
CA (1) | CA2557758C (ja) |
ES (1) | ES2436608T3 (ja) |
TW (1) | TWI369984B (ja) |
WO (1) | WO2005085195A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005092321A1 (ja) * | 2004-03-24 | 2005-10-06 | Kissei Pharmaceutical Co., Ltd. | 頻尿または尿失禁の予防または治療用医薬組成物 |
CN101027052A (zh) * | 2004-10-05 | 2007-08-29 | 橘生药品工业株式会社 | 用于伴下尿路梗阻的集尿障碍的预防和/或治疗剂 |
PL1806136T3 (pl) * | 2004-10-06 | 2012-04-30 | Kissei Pharmaceutical | Kompozycja medyczna do zapobiegania przejściu na leczenie operacyjne łagodnego rozrostu gruczołu krokowego |
WO2008106536A1 (en) * | 2007-02-28 | 2008-09-04 | Kissei Pharmaceuticals Co., Ltd. | Use of silodosin in a once daily administration for treating benign prostatic hyperplasia |
JP4497192B2 (ja) | 2007-11-08 | 2010-07-07 | 船井電機株式会社 | 光ディスク装置 |
RU2585727C1 (ru) * | 2014-12-12 | 2016-06-10 | Наталья Борисовна Гусева | Способ лечения детей с гиперактивным мочевым пузырем |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999015202A1 (fr) * | 1997-09-22 | 1999-04-01 | Kissei Pharmaceutical Co., Ltd. | Medicaments contre la dysurie resultant d'une hypertrophie de la prostate |
WO1999048530A1 (en) * | 1998-03-23 | 1999-09-30 | Merck & Co., Inc. | Combination therapy for the treatment of benign prostatic hyperplasia |
JP2000247998A (ja) * | 1999-02-26 | 2000-09-12 | Kissei Pharmaceut Co Ltd | α1Aアドレナリン受容体の変異体、当該変異体を用いた測定方法及び前立腺肥大に伴う排尿困難症治療剤 |
JP2001288115A (ja) * | 2001-02-07 | 2001-10-16 | Yamanouchi Pharmaceut Co Ltd | 下部尿路症治療剤 |
JP2002523449A (ja) * | 1998-09-01 | 2002-07-30 | ニトロメド インコーポレーテッド | ニトロソ化およびニトロシル化されたα−アドレナリン受容体拮抗薬、組成物および使用方法 |
JP4532274B2 (ja) * | 2002-09-06 | 2010-08-25 | キッセイ薬品工業株式会社 | 経口用固形医薬用結晶およびそれを含む排尿障害治療用経口用固形医薬 |
JP4633469B2 (ja) * | 2002-12-16 | 2011-02-16 | キッセイ薬品工業株式会社 | 経口固形医薬 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1432007A (en) | 1920-07-09 | 1922-10-17 | Ajax Metal Company | Tilting mechanism for furnaces and the like |
DE122010000031I1 (de) | 1992-12-02 | 2010-10-21 | Kissei Pharmaceutical | Indolin Verbindungen zur Behandlung von Dysurien |
US5932538A (en) * | 1996-02-02 | 1999-08-03 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses |
US5994294A (en) * | 1996-02-02 | 1999-11-30 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses |
US20020143007A1 (en) * | 1996-02-02 | 2002-10-03 | Garvey David S. | Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use |
US6410554B1 (en) * | 1998-03-23 | 2002-06-25 | Merck & Co., Inc. | Combination therapy for the treatment of benign prostatic hyperplasia |
-
2005
- 2005-02-23 JP JP2006510642A patent/JP5004215B2/ja not_active Expired - Fee Related
- 2005-02-23 KR KR1020067019606A patent/KR20070003968A/ko active Search and Examination
- 2005-02-23 CA CA2557758A patent/CA2557758C/en not_active Expired - Fee Related
- 2005-02-23 EP EP05719421.9A patent/EP1724257B1/en not_active Not-in-force
- 2005-02-23 US US10/598,533 patent/US20070167511A1/en not_active Abandoned
- 2005-02-23 WO PCT/JP2005/002913 patent/WO2005085195A1/ja active Application Filing
- 2005-02-23 ES ES05719421.9T patent/ES2436608T3/es active Active
- 2005-02-23 CN CN2005800071364A patent/CN1930123B/zh not_active Expired - Fee Related
- 2005-03-04 TW TW094106579A patent/TWI369984B/zh not_active IP Right Cessation
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999015202A1 (fr) * | 1997-09-22 | 1999-04-01 | Kissei Pharmaceutical Co., Ltd. | Medicaments contre la dysurie resultant d'une hypertrophie de la prostate |
WO1999048530A1 (en) * | 1998-03-23 | 1999-09-30 | Merck & Co., Inc. | Combination therapy for the treatment of benign prostatic hyperplasia |
JP2002523449A (ja) * | 1998-09-01 | 2002-07-30 | ニトロメド インコーポレーテッド | ニトロソ化およびニトロシル化されたα−アドレナリン受容体拮抗薬、組成物および使用方法 |
JP2000247998A (ja) * | 1999-02-26 | 2000-09-12 | Kissei Pharmaceut Co Ltd | α1Aアドレナリン受容体の変異体、当該変異体を用いた測定方法及び前立腺肥大に伴う排尿困難症治療剤 |
JP2001288115A (ja) * | 2001-02-07 | 2001-10-16 | Yamanouchi Pharmaceut Co Ltd | 下部尿路症治療剤 |
JP4532274B2 (ja) * | 2002-09-06 | 2010-08-25 | キッセイ薬品工業株式会社 | 経口用固形医薬用結晶およびそれを含む排尿障害治療用経口用固形医薬 |
JP4633469B2 (ja) * | 2002-12-16 | 2011-02-16 | キッセイ薬品工業株式会社 | 経口固形医薬 |
Also Published As
Publication number | Publication date |
---|---|
CN1930123B (zh) | 2010-06-23 |
ES2436608T3 (es) | 2014-01-03 |
CN1930123A (zh) | 2007-03-14 |
KR20070003968A (ko) | 2007-01-05 |
EP1724257A4 (en) | 2009-10-28 |
US20070167511A1 (en) | 2007-07-19 |
CA2557758A1 (en) | 2005-09-15 |
JPWO2005085195A1 (ja) | 2007-12-13 |
TW200533344A (en) | 2005-10-16 |
EP1724257A1 (en) | 2006-11-22 |
CA2557758C (en) | 2013-09-10 |
WO2005085195A1 (ja) | 2005-09-15 |
TWI369984B (en) | 2012-08-11 |
EP1724257B1 (en) | 2013-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4399862B2 (ja) | 腸疾患および内臓痛の治療薬 | |
JP5004215B2 (ja) | 神経障害に伴う過活動膀胱の予防または治療用医薬組成物 | |
ZA200603181B (en) | 3-(4-aminophenyl) thienopyrimid-4-one derivatives as MCH R1 antagonists for the treatment of obesity, diabetes, depression and anxiety | |
MXPA05004925A (es) | Remedio para vejiga hiperactiva que incluye derivado de anilida de acido acetico como el ingrediente activo. | |
WO2006088193A1 (ja) | 抗腫瘍剤 | |
JPWO2009057685A1 (ja) | 過活動膀胱治療用医薬組成物 | |
KR20060017763A (ko) | 치료에 사용하는 아제티딘카르복스아미드 유도체의 용도 | |
JPWO2005079845A1 (ja) | 片頭痛予防薬 | |
CA2149691A1 (en) | Medicament for therapeutic and prophylactic treatment of diseases caused by smooth muscle cell hyperplasia | |
JP4998258B2 (ja) | 過敏性腸症候群の治療薬 | |
US20100137399A1 (en) | Preventive and/or therapeutic agent for urine collection disorder accompanying lower urinary tract obstruction | |
PT80805B (pt) | Processo para a preparacao de derivados de fluorolilamina | |
CN1198822C (zh) | 具血管生成抑制性的噻二唑基哒嗪衍生物 | |
WO2006088080A1 (ja) | シクロヘプタ[b]ピリジン-3-カルボニルグアニジン誘導体およびそれを含有する医薬品 | |
JPH0714871B2 (ja) | 筋弛緩剤 | |
US6649623B1 (en) | Cyclic amine derivatives and use thereof | |
WO2001000613A1 (fr) | Composes de benzimidazole et medicaments les contenant | |
JPH083045A (ja) | 排尿障害改善薬 | |
WO2020146878A1 (en) | Salt and crystalline forms of rapastinel | |
JPH0753363A (ja) | 頻尿治療剤 | |
US20090163571A1 (en) | Pharmaceutical for use in the treatment of ureterolithiasis | |
WO2006077846A1 (ja) | 注意欠陥/多動性障害治療薬 | |
WO2001040225A1 (fr) | Traitement curatif ou preventif pour polyurie ou incontinence urinaire | |
JP2006076913A (ja) | イソインドール誘導体 | |
JP2003246732A (ja) | 1,2−エタンジオール誘導体またはその塩を含有する神経断裂治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080116 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110208 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111206 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120222 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120321 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120515 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120517 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150601 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5004215 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |